Company Overview and News

10
Tencent-backed Meituan jumps 5 percent on debut in positive signal for HK IPOs

1h theedgemarkets
HONG KONG (Sep 20): Meituan Dianping soared on debut in Hong Kong on Thursday, valuing the Chinese online food delivery-to-ticketing services firm at about $55 billion and sending a positive signal to companies lining up to list in the financial hub.
BABA 0700 TRI MS

10
UPDATE 2-Tencent-backed Meituan jumps 5 pct on debut in positive signal for HK IPOs

2h reuters
HONG KONG (Reuters) - Meituan Dianping (3690.HK) soared on debut in Hong Kong on Thursday, valuing the Chinese online food delivery-to-ticketing services firm at about $55 billion and sending a positive signal to companies lining up to list in the financial hub.
BABA 0700 MS

 
Red Hat, Inc. (RHT) CEO Jim Whitehurst on Q2 2019 Results - Earnings Call Transcript

2h seekingalpha
Good day, everyone, and welcome to the Red Hat’s Second Quarter Fiscal Year 2019 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] I will be standing by if you should need any assistance.
DB MS RHT

6
SP 500, Dow up as rising treasury yields boost banks

2h moneycontrol
The S&P 500 and the Dow Jones industrial average rose on Wednesday, with the Dow hitting its highest closing level since late January as rising Treasury yields boosted the financial sector and trade worries subsided.
FB GOOGL AAPL GOOG MS

 
Kingfisher PLC (KGFHF) CEO Véronique Laury on Q2 2018 Results - Earnings Call Transcript

6h seekingalpha
Good morning, everyone. Welcome to all of you this morning. Today is an important moment in our transformation. We almost are halfway through. Today, I'm going to talk about 4 things. The first one is why our transformation is vital, probably even more than when we started this journey. The second one is why our transformation is going to deliver the expected benefit. The third one is why our transformation is tough and what are the issues we are currently facing because we are facing issues.
KGF MS KGFHF

6
S&P 500, Dow up as rising treasury yields boost banks

6h theedgemarkets
NEW YORK (Sept 20): The S&P 500 and the Dow Jones industrial average rose on Wednesday, with the Dow hitting its highest closing level since late January as rising Treasury yields boosted the financial sector and trade worries subsided.
FB GOOGL AAPL GOOG MS

6
S&P 500, Dow up as rising treasury yields boost banks

6h malaymail
NEW YORK, Sept 20 ― The S&P 500 and the Dow Jones industrial average rose yesterday, with the Dow hitting its highest closing level since late January as rising Treasury yields boosted the financial sector and trade worries subsided.
FB GOOGL AAPL GOOG MS

 
Elanco Animal Health prices IPO above expected range

8h marketwatch
Elanco Animal Health Inc. ELAN, +0.00% priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. LLY, -1.07% priced shares at $24 a piece. Earlier in the month, Elanco had estimated shares in the $20 to $23 range. Under current pricing, Elanco hopes to raise up to $1.74 billion on an offering of 62.9 million shares with an added 9.
DTK MS

6
S&P 500, Dow up as rising treasury yields boost banks

9h channelnewsasia
U.S. stock markets headed for a flat open on Wednesday, holding just off three-week highs after brushing aside the latest blows in Washington and Beijing's trade war.
FB GOOGL AAPL GOOG MS

6
S&P 500, Dow up as rising treasury yields boost banks

9h reuters
NEW YORK (Reuters) - The S&P 500 and the Dow Jones industrial average rose on Wednesday, with the Dow hitting its highest closing level since late January as rising Treasury yields boosted the financial sector and trade worries subsided.
FB GOOGL AAPL GOOG MS

60
6 Big Bank Stocks Leading the Breakout

9h investorplace
The Dow Jones Industrial Average is pushing to a new record high on Wednesday, lifting toward the 26,500 level, as the financial sector gets a huge lift from rising long-term interest rates. This is the offset from the weakness hitting the bond market, with the 10-year Treasury yield pushing well past the 3% threshold to move near levels not seen since 2011.
BAC USB GS C JPM MS

3
GWPH Stock Surges on Reclassification of Epidiolex

9h investorplace
GW Pharmaceuticals (NASDAQ:GWPH) shares were surging on Wednesday as the U.S. Drug and Enforcement Administration (DEA) has plans to reclassify one of its medications.
GWPH MS GWP

2
Stuart Varney of Fox Business News and the Lessons of the 2008 Financial Crisis

11h investorplace
Fox Business News Anchor Stuart Varney was reporting from Wall Street during the thick of the 2008 financial crisis. As the investing world marks 10 years since those events unfolded, InvestorPlace asked him about his memories of that time and to provide his take on what investors should have learned from those dark days.
MS AIG

6
US STOCKS-Financials boost S&P 500, Dow; tech drags on Nasdaq

11h reuters
(For a live blog on the U.S. stock market, click or type LIVE/ in an Eikon news window.)
FB GOOGL AAPL GOOG MS

 
Banks lift S&P, Dow; Nasdaq weighed by Microsoft

13h reuters
(Reuters) - The S&P 500 and the Dow Jones Industrials Average rose on Wednesday, helped by upbeat housing data and a gain for bank stocks driven by rising Treasury yields, while the tech-heavy Nasdaq was weighed by a drop in Microsoft.
CPRT MS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 61762V507